Article

Diagnostic profile measures stone formation risk factors

Mission Pharmacal offers the StoneRisk Diagnostic Profile, which measures10 urine risk factors for stone formation. It offers a urine collectionand preservation system and is recommended for initial and recurrent stoneformers who test positive for a urinary tract infection, according to thecompany. Test results are shown on a computer-generated graphic display.

Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, answers a question during a Zoom video interview
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
1 expert in this video
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
1 expert in this video
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
1 expert in this video
Adoption of New Treatment Modalities to Treat BPH
1 expert is featured in this series.
Safety data on Black patients from ARANOTE
2 experts are featured in this series.
Current Unmet Needs in ccRCC Diagnosis
2 experts are featured in this series.
Decision-Making in Small Renal Masses
Related Content
Subcutaneous nivolumab approved in EU, Canada for solid tumors
May 28th 2025

Subcutaneous nivolumab approved in EU, Canada for solid tumors

Hannah Clarke
The approvals are supported by findings from the phase 3 CheckMate-67T trial.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
May 27th 2025

Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test

Hannah Clarke
The single-use test can deliver diagnostic results for chlamydia and gonorrhea in approximately 30 minutes.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Kidney stones | Image Credit: © airborne77 - stock.adobe.com
May 26th 2025

Clarifying CPT 52353 billing for same-side stone cases

Jonathan Rubenstein, MD Mark Painter
Jonathan Rubenstein, MD, and Mark Painter tackle a coding question for treating stones.
Expert discusses the promise of emerging MISTs for BPH
May 23rd 2025

Expert discusses the promise of emerging MISTs for BPH

James C. Ulchaker, MD Hannah Clarke
James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.
© 2025 MJH Life Sciences

All rights reserved.